Real-world two-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies.
Conclusions: In this real-world study of use of biologic PsA therapies, 24-month persistence was low (19.7%), and treatment was frequently supplemented with adjunctive medications.
PMID: 32271088 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Arthritis | Corticosteroid Therapy | Enbrel | Humira | Psoriatic Arthritis | Research | Rheumatology | Stelara | Study